Dulaglutide

Background

Dulaglutide is a long‑acting glucagon‑like peptide‑1 receptor agonist (GLP‑1 RA) developed by Eli Lilly and marketed as Trulicity for the treatment of type 2 diabetes mellitus (T2DM).[11][12][13] It was designed as a once‑weekly, injectable peptide therapeutic to improve glycemic control with low intrinsic risk of hypoglycemia and modest weight reduction.[11][12] Dulaglutide is a fusion protein consisting of two identical GLP‑1 analog sequences covalently linked to a modified human IgG4 Fc fragment, which prolongs its half‑life by increasing molecular size and enabling Fc‑mediated recycling.[11][12][3]

The molecule was discovered in the context of efforts to improve on earlier, shorter‑acting GLP‑1 RAs such as exenatide and liraglutide by extending dosing intervals and enhancing patient adherence.[11][12] Dulaglutide received FDA approval in 2014 as the third once‑weekly GLP‑1 RA for adults with T2DM, as an adjunct to diet and exercise.[11][13] It has since been approved in multiple regions, including the European Union and Australia, and is incorporated into major diabetes treatment guidelines as a GLP‑1 RA option.[12][14]

Mechanism of action

Dulaglutide is a selective agonist of the GLP‑1 receptor (GLP‑1R), a class B G protein‑coupled receptor expressed on pancreatic β‑cells and other tissues relevant to glucose and energy homeostasis.[11][12][9]

Key mechanistic features include:

• Glucose‑dependent insulin secretion: By activating GLP‑1R on pancreatic β‑cells, dulaglutide enhances cyclic AMP signaling and increases insulin secretion in a glucose‑dependent manner, thereby lowering postprandial and fasting plasma glucose.[11][12][14]
• Suppression of glucagon: Dulaglutide reduces inappropriate postprandial glucagon secretion from pancreatic α‑cells, which decreases hepatic glucose production.[11][12]
• Delayed gastric emptying: GLP‑1R activation slows gastric emptying, attenuating the rate of glucose absorption and blunting postprandial glycemic excursions.[11][12]
• Effects on appetite and body weight: Dulaglutide acts on GLP‑1 receptors in the central nervous system and gastrointestinal tract to reduce appetite and energy intake, contributing to modest weight loss in many patients with T2DM.[11][12][14]
• Cardiorenal effects (class‑consistent): GLP‑1 RAs, including dulaglutide, have been associated with improvements in cardiovascular risk factors (e.g., weight, blood pressure) and renal parameters; dulaglutide specifically has demonstrated cardiovascular benefit in a dedicated outcome trial (REWIND).[9][11]

The IgG4 Fc fusion increases molecular size beyond the renal filtration threshold and promotes neonatal Fc receptor (FcRn) recycling, resulting in a prolonged terminal half‑life (~4–5 days) and enabling once‑weekly dosing.[11][12][15] Structural analyses have further explored charge heterogeneity and post‑translational modifications in dulaglutide that may influence stability and activity.[3]

Evidence summary

Glycemic efficacy and weight effects

Dulaglutide’s efficacy and safety have been extensively evaluated in the AWARD phase 3 program, a series of randomized controlled trials in adults with T2DM across various background therapies.[12][14]

Representative trials include:

• AWARD‑1: In 978 patients inadequately controlled on metformin plus pioglitazone, once‑weekly dulaglutide 1.5 mg significantly reduced HbA1c versus exenatide twice daily at 26 weeks, with greater proportions achieving HbA1c <7%.[12]
• AWARD‑2: In 807 patients on metformin and glimepiride, dulaglutide 1.5 mg was non‑inferior and statistically superior to insulin glargine for HbA1c reduction at 52 weeks.[14]
• AWARD‑3: In 807 drug‑naïve patients, dulaglutide 1.5 mg showed greater HbA1c reduction than metformin at 26 weeks (mean reduction 8.5 mmol/mol [0.78%] vs 6.1 mmol/mol [0.56%]) and a higher proportion achieving HbA1c <53 mmol/mol (7%) (62% vs 54%), with benefits maintained to 52 weeks.[14]
• AWARD‑5 and others: Additional studies demonstrated efficacy as monotherapy and in combination with oral agents and insulin, typically yielding HbA1c reductions of ~0.8–1.5 percentage points and modest weight loss (1–3 kg) depending on dose and baseline characteristics.[11][12][14]

An early evidence‑based review concluded that dulaglutide has glycemic efficacy similar to or greater than other newer GLP‑1 RAs, with low hypoglycemia risk except when combined with insulin or sulfonylureas.[12]

Cardiovascular outcomes

The REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) trial was a large, placebo‑controlled, cardiovascular outcomes study of dulaglutide.[11]

• Population: Approximately 9,900 patients with T2DM, with a majority having multiple risk factors and a minority with established cardiovascular disease.[11]
• Intervention: Dulaglutide 1.5 mg once weekly versus placebo, added to standard of care.[11]
• Outcome: Dulaglutide significantly reduced the risk of the composite 3‑point major adverse cardiovascular event (MACE) endpoint (non‑fatal myocardial infarction, non‑fatal stroke, cardiovascular death) compared with placebo over a median follow‑up exceeding 5 years.[11]

These results support a cardiovascular risk reduction indication for dulaglutide in adults with T2DM and established cardiovascular disease or multiple risk factors, consistent with contemporary GLP‑1 RA data.[11]

Pharmacokinetics and bioequivalence

A phase 1, randomized, parallel‑group study in 138 healthy Chinese male subjects compared the pharmacokinetics, safety, and immunogenicity of a proposed biosimilar (HEC14028) with reference dulaglutide (Trulicity).[15]

• Single subcutaneous dose; 17‑day PK observation period.[15]
• Primary PK parameters (Cmax and AUC) were within predefined bioequivalence margins.[15]
• Safety and immunogenicity profiles were similar between products, with mainly mild gastrointestinal adverse events.[15]

Structural characterization

Analytical work using dual‑mode anion‑exchange chromatography and orthogonal characterization demonstrated that dulaglutide exhibits charge heterogeneity related to microheterogeneity such as phosphorylation, sialylation, deamidation, oxidation, truncation, and aggregation.[3] Basic variants tended to show non‑covalent aggregation, whereas acidic variants included covalently linked aggregates, with potential implications for structure–activity relationships and quality control.[3]

Clinical and research uses

Approved therapeutic uses

• Type 2 diabetes mellitus (T2DM): Dulaglutide is approved as a once‑weekly, subcutaneous GLP‑1 RA for adults with T2DM to improve glycemic control as an adjunct to diet and exercise.[11][13][14]
• Cardiovascular risk reduction in T2DM: Based on REWIND, dulaglutide is approved in some jurisdictions to reduce the risk of MACE in adults with T2DM and established cardiovascular disease or multiple cardiovascular risk factors.[11]

Dulaglutide can be used:

• As monotherapy when metformin is contraindicated or not tolerated.[12][14]
• As add‑on therapy to metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitors, and/or insulin when glycemic targets are not achieved.[11][12][14]

Investigational and off‑label contexts

Published literature indicates ongoing or exploratory research in:

• Renal and hepatic outcomes in T2DM, including effects on albuminuria and non‑alcoholic fatty liver disease (NAFLD), though evidence remains limited to secondary analyses and small studies.[9][14]
• Cancer‑related outcomes: Integrative analyses of GLP‑1R expression and survival across tumor types consider the implications of GLP‑1 RA exposure (including dulaglutide), but causal relationships remain uncertain and no oncologic indication exists.[6][9]

Use for obesity without T2DM is not an approved indication; other GLP‑1 RAs have dedicated obesity approvals, whereas dulaglutide’s role in weight management is largely confined to patients with T2DM.[9]

Dosing context

Dulaglutide is administered as a once‑weekly subcutaneous injection via pre‑filled, single‑use pen or syringe.[11][13][14]

• Clinical development and post‑approval literature most commonly reference 0.75 mg and 1.5 mg once weekly as standard maintenance doses for glycemic control in adults with T2DM.[11][13][14]
• Dose selection in trials has considered baseline HbA1c, prior therapies, and tolerability, with higher doses generally providing greater HbA1c reduction and weight loss at the expense of more gastrointestinal adverse events.[11][12][14]
• Doses are given without regard to meals, typically in the abdomen, thigh, or upper arm, with rotation of injection sites.[11][13]

These dosing details are descriptive of clinical trial and labeling practice and are not prescriptive.

Safety profile

Common adverse effects

Across the AWARD program and post‑marketing data, the most frequently reported adverse reactions are gastrointestinal:[11][12][13][14]

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain and dyspepsia

These events are generally mild to moderate, most prominent at treatment initiation or dose escalation, and often diminish over time.[11][12]

Other commonly observed effects include:

• Decreased appetite and weight loss, typically modest in magnitude.[11][12]
• Injection‑site reactions, usually mild.[11][13]
• Small increases in heart rate (class effect for GLP‑1 RAs).[11][12]

Hypoglycemia

Dulaglutide alone or with metformin is associated with low rates of hypoglycemia, attributable to glucose‑dependent insulin secretion.[11][12][14] However, when combined with sulfonylureas or insulin, symptomatic and sometimes severe hypoglycemia occurs more frequently, consistent with additive pharmacodynamic effects.[11][12]

Pancreatitis and gallbladder disease

Cases of acute pancreatitis have been reported in dulaglutide‑treated patients, as with other GLP‑1 RAs.[11][12] Causality is not fully established, but product labeling typically includes warnings, recommendations to discontinue dulaglutide if pancreatitis is suspected, and caution in patients with a history of pancreatitis.[11]

GLP‑1 RAs have also been associated with gallbladder‑related events (e.g., cholelithiasis, cholecystitis), though data are not specific to dulaglutide alone.[11][12]

Thyroid C‑cell tumors

Rodent studies with long‑acting GLP‑1 RAs, including dulaglutide, have shown an increased incidence of thyroid C‑cell tumors, including medullary thyroid carcinoma (MTC).[11][13] The relevance of these findings to humans is uncertain, but dulaglutide labeling includes a boxed warning in some jurisdictions and contraindications in individuals with personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN2).[11][13]

Immunogenicity

Due to its peptide–protein nature, dulaglutide can induce anti‑drug antibodies, although available data suggest low incidence and minimal impact on efficacy or safety in most patients.[11][12][15] The biosimilar PK study also reported low rates of treatment‑emergent anti‑dulaglutide antibodies.[15]

Other safety considerations

• Mild to moderate injection‑site reactions and gastrointestinal intolerance are the main reasons for discontinuation in clinical trials.[11][12]
• No consistent signal of increased overall cancer risk has been established; ongoing analyses continue to monitor long‑term safety.[6][9]

Contraindications and precautions

Based on regulatory documents and reviews, dulaglutide is typically contraindicated in:[11][13]

• Patients with a personal or family history of medullary thyroid carcinoma (MTC).
• Patients with multiple endocrine neoplasia syndrome type 2 (MEN2).
• Patients with known serious hypersensitivity to dulaglutide or any of its components.

Cautions and warnings include:[11][12][13]

• History of pancreatitis.
• Severe gastrointestinal disease, particularly severe gastroparesis, as GLP‑1 RAs slow gastric emptying.
• Use with insulin or insulin secretagogues, where dose adjustment of the latter may be needed to reduce hypoglycemia risk.
• Monitoring in patients with renal impairment, particularly when severe gastrointestinal adverse events may precipitate volume depletion.

Regulatory status

United States

The U.S. Food and Drug Administration (FDA) initially approved Trulicity (dulaglutide) in 2014 as a once‑weekly GLP‑1 RA for adults with T2DM, as an adjunct to diet and exercise.[11][13] Dulaglutide is available as pre‑filled, single‑use pens or syringes containing fixed doses (e.g., 0.75 mg and 1.5 mg per 0.5 mL solution).[13] Subsequent labeling updates incorporated cardiovascular outcomes data from REWIND, supporting an indication for reduction of MACE in adults with T2DM and established cardiovascular disease or multiple risk factors.[11]

Dulaglutide is not approved in the U.S. for type 1 diabetes or for weight management in the absence of T2DM.

European Union and other regions

The European Medicines Agency (EMA) has authorized dulaglutide as a once‑weekly GLP‑1 RA for adults with T2DM, with indications and contraindications broadly aligned with U.S. labeling, including thyroid C‑cell tumor warnings based on rodent data and pancreatitis precautions.[11][12] The product is also approved in other markets (e.g., Australia), where national formularies describe its role as an add‑on therapy in T2DM when oral agents are insufficient.[14]

Across jurisdictions, dulaglutide is regulated as a prescription‑only, parenteral peptide therapeutic with post‑marketing surveillance for long‑term safety, particularly regarding pancreatitis, thyroid neoplasia, and cardiovascular and renal outcomes.[11][12]